相关实验视频

Updated: Jan 11, 2026

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

佩斯卡迪洛核糖体生物发生因子1作为瘤免疫治疗中的治疗点

Jia Yu¹, Bo Yu², Fei-Lin Ge³

¹Department of Infectious Diseases, State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China.

World journal of gastroenterology

|November 19, 2025

概括

佩斯卡迪洛核糖体生物发生因子1 (PES1) 与癌症预后不佳有关. 这项研究发现,PES1与胃癌中PD-L1等免疫逃避标志物相关,这表明PES1是潜在的免疫治疗标.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
分子生物学分子生物学

背景情况:

高 pescadillo 核糖体生物发生因子1 (PES1) 表达与各种癌症的预后不佳有关.
之前的研究表明,PES1与编程死亡连接体1 (PD-L1) 相对相关,并且在胃癌和头癌中具有不良特征.
PES1和PD-L1之间的确切关系需要进一步阐明.

研究的目的:

研究胃癌中PES1表达和免疫标志物之间的相关性.
探索PES1在调节免疫逃避中的潜在作用.
确定PES1作为癌症免疫治疗的潜在治疗标.

主要方法:

癌症基因组图谱 (TCGA) 胃腺癌数据集的分析.
评估PES1表达,PD-L1表达和CD8+T细胞透之间的相关性.
假设潜在的调节途径 (PI3K/AKT,Myc).

主要成果:

在PES1表达和CD8+T细胞透之间观察到负相关性.
在PES1表达和PD-L1表达之间发现了正相关性.
PES1可能调节PD-L1的表达,可能会影响免疫逃避.

结论:

PES1的表达与免疫细胞透的改变和胃癌中的PD-L1水平有关.
PES1可能作为免疫逃避的调节者.
对于未来的癌症免疫治疗策略来说,PES1是一个有希望的目标.

关键词:

免疫规避机制的免疫规避机制佩斯卡迪洛核糖体生物发生因子1 编程死亡联手 1 编程死亡联手 1 瘤的免疫规避是瘤的免疫规避.瘤免疫疗法免疫疗法

更多相关视频

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Published on: June 2, 2021

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...